These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 33929995)

  • 41. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
    Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New therapeutic agents in gastrointestinal stromal tumours.
    Falkenhorst J; Hamacher R; Bauer S
    Curr Opin Oncol; 2019 Jul; 31(4):322-328. PubMed ID: 31033566
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Thymic malignancies: emerging systemic therapies.
    Girard N
    Curr Opin Oncol; 2019 Sep; 31(5):454-460. PubMed ID: 31394557
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review.
    Chen LT; Oh DY; Ryu MH; Yeh KH; Yeo W; Carlesi R; Cheng R; Kim J; Orlando M; Kang YK
    Cancer Res Treat; 2017 Oct; 49(4):851-868. PubMed ID: 28052652
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular-targeted first-line therapy for advanced gastric cancer.
    Song H; Zhu J; Lu D
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD011461. PubMed ID: 27432490
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer.
    Matos I; Elez E; Capdevila J; Tabernero J
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):267-82. PubMed ID: 27578253
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapy.
    Rossi A; Maione P; Sacco PC; Ambrosio R; Falanga M; Gridelli C
    Curr Drug Targets; 2010 Jul; 11(7):865-8784. PubMed ID: 20412044
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The latest advances in chemotherapy for gastrointestinal cancers.
    Ohtsu A
    Int J Clin Oncol; 2003 Aug; 8(4):234-8. PubMed ID: 12955579
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting c-MET/HGF signaling pathway in upper gastrointestinal cancers: rationale and progress.
    Gholamin S; Fiuji H; Maftouh M; Mirhafez R; Shandiz FH; Avan A
    Curr Drug Targets; 2014; 15(14):1302-11. PubMed ID: 25382190
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeted therapies and predictive markers in epithelial malignancies of the gastrointestinal tract.
    McIntire M; Redston M
    Arch Pathol Lab Med; 2012 May; 136(5):496-503. PubMed ID: 22229849
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dermatologic adverse events to targeted therapies in lower GI cancers: clinical presentation and management.
    Belum VR; Cercek A; Sanz-Motilva V; Lacouture ME
    Curr Treat Options Oncol; 2013 Sep; 14(3):389-404. PubMed ID: 23996476
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Qi YT; Hou Y; Qi LC
    Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeted treatments of sarcomas and connective tumors beside gastrointestinal stromal tumor.
    Martin-Broto J; Hindi N
    Curr Opin Oncol; 2016 Jul; 28(4):338-44. PubMed ID: 27166665
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.
    Kienle DL; Stilgenbauer S
    Expert Opin Pharmacother; 2020 Jun; 21(8):917-929. PubMed ID: 32162560
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions.
    Bauer S; Joensuu H
    Drugs; 2015 Aug; 75(12):1323-34. PubMed ID: 26187774
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
    Zhao HF; Wang J; Shao W; Wu CP; Chen ZP; To ST; Li WP
    Mol Cancer; 2017 Jun; 16(1):100. PubMed ID: 28592260
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours.
    Foo T; Goldstein D; Segelov E; Shapiro J; Pavlakis N; Desai J; Yip D; Zalcberg J; Price TJ; Nagrial A; Chantrill L; Burge M; Karapetis CS; Tebbutt N; Roy AC
    Target Oncol; 2022 Mar; 17(2):95-110. PubMed ID: 35290591
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Imatinib treatment of metastatic GIST: don't stop (believing).
    Heinrich MC
    Lancet Oncol; 2010 Oct; 11(10):910-1. PubMed ID: 20864404
    [No Abstract]   [Full Text] [Related]  

  • 60. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
    Teoh D; Secord AA
    Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.